At 22:45 on August 1, 2019, Immuron Ltd (IMRN.us) shares fluctuated and their share prices plummeted 5.60%. As of press time, the stock was trading at US $3.37 per share, with a turnover of 4747 shares, a turnover rate of 0.12% and an amplitude of 6.53%.

The latest 2018-12-31 data show that the stock achieved operating income of $708526.00, net profit of-$1.15 million, earnings per share of-$0.34, gross profit of $538951.22, and price-to-earnings ratio of-5.93 times.

In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.

The biotech industry in which Immuron Ltd shares are located rose 1.91 per cent as a whole. Among its related stocks, Vanda Pharmaceuticals Inc,AVEO Pharmaceutical Co., Aileron Therapeutics Inc rose a lot, Can Fite Biofarma Ltd, Delmar Pharmaceuticals Inc and Sellas Life Sciences Group Inc were more active, and the turnover rates were 38.58%, 10.68% and 9.87%, respectively. The related stocks with larger amplitudes were Can Fite Biofarma Ltd, Nanostring Technologies Inc and Bellerophon Therapeutics Inc, with amplitudes of 22.57%, 19.72% and 19.64%, respectively.

About Immuron Ltd: Immuron is a biopharmaceutical company that develops polyclonal antibodies for the treatment and prevention of diseases. Its products include Travelan, IMM-124E for the treatment of NASH, and IMM-529 for Clostridium labile infection.

(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )